• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dermatology

The AJMC® Dermatology compendium is a comprehensive resource for clinical news and expert insights for diseases related to the skin, hair, and nails.

Latest News

FDA-approval expanded treatment of ruxolitinib for patients with non-immunocomprimised mild to severe atopic dermatitis. | Image Credit: @maggie-sora.chatgpt.com.png.
FDA Approves Ruxolitinib Cream for Patients as Young as 2 Years With Atopic Dermatitis

September 19th 2025

Ruxolitinib cream received an expanded approval to treat patients as young as 2 years old with non-immunocompromised mild to severe atopic dermatitis.

By week 12 of treatment with ruxolitinib cream, the majority of patients with nonsegmental vitiligo experienced significant repigmentation. | Image credit: etonastenka - stock.adobe.com
Efficacy of Ruxolitinib Cream in Nonsegmental Vitiligo Confirmed in Real-World Study

September 18th 2025

While atopic dermatitis was found to be the most burdensome disease and received the most grants, the correlation between disease burden and NIH funding deteriorated as the investigators went down the list of burdensome diseases. | Image credit: GRON777 - stock.adobe.com
NIH Pediatric Dermatology Spending Misaligned With Disease Burden

September 4th 2025

Four weeks of therapy with ruxolitinib led to a significant benefit on numerous assessments. | Image Credit: Peakstock - stock.adobe.com
Managing Both Physical, Mental Health Key for QOL in Vitiligo

August 23rd 2025

AJMC Q&A with Elizabeth Garcia Creighton | Background image credit: ipopba - stock.adobe.com
Navigating Challenges in Pediatric Dermatology Access, Addressing Disparities: Elizabeth Garcia Creighton

August 17th 2025

More News

© 2025 MJH Life Sciences
AJMC®
All rights reserved.